Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a report issued on Saturday.

Several other equities analysts have also issued reports on ENTA. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Stock Up 4.7%

NASDAQ ENTA opened at $14.10 on Friday. The company has a 50-day simple moving average of $13.48 and a two-hundred day simple moving average of $13.46. Enanta Pharmaceuticals has a 12-month low of $7.05 and a 12-month high of $17.15. The firm has a market cap of $410.59 million, a price-to-earnings ratio of -5.85 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The company had revenue of $14.36 million during the quarter, compared to analysts’ expectations of $16.76 million. Equities analysts expect that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 674.7% during the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after acquiring an additional 311,010 shares in the last quarter. Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after acquiring an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Enanta Pharmaceuticals by 5.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 6,549 shares during the period. Invesco Ltd. increased its position in Enanta Pharmaceuticals by 4.3% during the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 2,607 shares during the period. Finally, Marshall Wace LLP raised its holdings in Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.